Magenta Therapeutics Inc (NASDAQ:MGTA) reached a new 52-week low during trading on Friday . The company traded as low as $11.32 and last traded at $11.69, with a volume of 5070 shares trading hands. The stock had previously closed at $11.90.

A number of equities research analysts recently commented on the stock. Zacks Investment Research cut shares of Magenta Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday. Cowen assumed coverage on shares of Magenta Therapeutics in a research note on Monday, July 16th. They set an “outperform” rating on the stock. JPMorgan Chase & Co. assumed coverage on shares of Magenta Therapeutics in a research note on Monday, July 16th. They set an “overweight” rating and a $18.00 price target on the stock. Goldman Sachs Group assumed coverage on shares of Magenta Therapeutics in a research note on Monday, July 16th. They set a “buy” rating and a $18.00 price target on the stock. Finally, Wedbush assumed coverage on shares of Magenta Therapeutics in a research note on Monday, July 16th. They set an “outperform” rating and a $22.00 price target on the stock. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $19.33.

Magenta Therapeutics (NASDAQ:MGTA) last issued its quarterly earnings results on Thursday, August 9th. The company reported ($3.13) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($2.03). sell-side analysts predict that Magenta Therapeutics Inc will post -2.8 earnings per share for the current year.

In related news, Director David Scadden purchased 6,600 shares of the business’s stock in a transaction on Monday, June 25th. The shares were acquired at an average price of $15.00 per share, for a total transaction of $99,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

Several large investors have recently added to or reduced their stakes in MGTA. Casdin Capital LLC acquired a new stake in shares of Magenta Therapeutics in the second quarter worth $27,484,000. Opaleye Management Inc. acquired a new stake in shares of Magenta Therapeutics in the second quarter worth $7,425,000. Laurion Capital Management LP acquired a new stake in shares of Magenta Therapeutics in the second quarter worth $4,725,000. Harvard Management Co. Inc. acquired a new stake in shares of Magenta Therapeutics in the second quarter worth $4,490,000. Finally, Voya Investment Management LLC acquired a new stake in shares of Magenta Therapeutics in the second quarter worth $3,387,000. Hedge funds and other institutional investors own 30.27% of the company’s stock.

About Magenta Therapeutics (NASDAQ:MGTA)

Magenta Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases.

Featured Story: How Buying a Call Option Works

Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.